Expharmaguy
The share price is dropping but there is no evidence that the stock is failing because of a fundamental change in the the Alpha 3 or ALLO-329 story. In fact, the opposite is true. Alpha 3 remains on track; the futility analysis was good enough for FDA to grant RMAT & fast track designations; the company ended 3Q w 389 M in cash, and enrollment momentum is continuing. So the conclusion is that the price is dropping because the major inflection points are 6-18 months away. For long term investors that means a buying opportunity. I continue to accumulate. Opinion only not advice. $ALLO
9

:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Flarge_Getty_Images_2242061820_jpg_9583618064.webp)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault36.jpg)